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Do we need targeting to speciﬁc liver cells? Uptake of drugs in
the liver is usually high. While most existing drugs are not cell-
speciﬁc at all, they are effective. However, uptake by ﬁbrogenic
cells in the ﬁbrotic liver is usually low and off-target effects can
be high, e.g., due to compromised hepatic metabolism and excre-
tion. Therefore, most experimental drugs are not effective at the
preclinical level when they are administered in animals with
advanced and established ﬁbrosis (i.e. a situation similar to the
clinical practice). To date, no antiﬁbrotic drug has reached the
clinic.
Some drugs are intrinsically targeted to the ﬁbrogenic process
due to their (receptor) speciﬁcity. Examples are PDGFRb or inte-
grin aVb6 antagonists/blocking antibodies, or liposomal apta-
mers or siRNA against procollagen I, but even here delivery to
their target cells in advanced ﬁbrotic livers may be limited.Rationale for drug targeting
 The hepatic uptake of (xenobiotic) drugs largely occurs via
hepatocytes and/or macrophages, not by myoﬁbroblast-like
cells which are the key effector cells in ﬁbrogenesis.
 Biologicals like chemokines, cytokines or prostaglandins have
a short plasma half life and the ubiquitous expression of their
receptors can induce unwanted side effects.
 Interference with normal matrix turnover and wound healing
may restrict the use of untargeted antiﬁbrogenic drugs for
prolonged periods of time.
 Inhibition of inﬂammation may lead to inhibition of ECM
turnover and thus to enhanced ﬁbrogenesis (skewing of the
immune system towards alternative macrophages, a Th2 T cell
response, or production of TGFb).Journal of Hepatology 20
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translocation from the intestine combined with a compro-
mised immune system in cirrhotic patients prevent the
chronic administration of generally active immunosuppres-
sive drugs.
 An enhanced risk of tumorgenesis or metastasis in the ﬁbrotic
(virus infected) liver precludes the use of anti-apoptotic drugs
or drugs that enhance MMP activity due to an increased per-
ceived risk of tumorgenesis and metastasis.
 Induction of splanchnic and peripheral hypotension restricts
the systemic use of drugs that reduce portal hypertension.How to reach the target cells (Fig. 1)
Activated hepatic stellate cells/myoﬁbroblasts (Table 1)
 Proteins/peptides/sugars:11 voRGD-modiﬁed proteins targeted at the collagen type VI
receptor,
proteins modiﬁed with peptides that bind to the platelet
derived growth factor b (PDGFb)-receptor,
mannose-6-phosphate (M6P) substituted proteins targeted
at the M6P-insulin-like growth factor II (IGFII) receptor. Viruses modiﬁed with PDGF-b-binding peptides or adeno-
viral transfection targeted at HSC-speciﬁc promotors and
genes.
 Antibodies: human single chain antibodies against Synapto-
physin, (C1–3 ScAb).
 Vitamin A containing liposomes.Kupffer cells (KC) and sinusoidal endothelial cells (SEC)
Carriers modiﬁed with:
 mannose targeted at CD206 (M2 macrophages),
 fucose moieties targeted at the fucose receptor (KC),
 succinylated/aconylated proteins targeted at scavenger
receptors on SEC and/or KC (CD36, CD68/macrosialin, LOX-1,
SREC-1),
 hyaluronic acid targeted at the hyaluronan receptor CD44
(SEC).
 Nanoparticles: adsorptive pinocytosis: non-receptor mediated
uptake of high molecular weight particles, e.g., clodronate lip-
osomes (KC).l. 55 j 726–728
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Fig. 1. Drug targeting in the liver. (A) Cell-speciﬁc ligands directed at resident hepatic cells that can be used for targeted therapies of liver ﬁbrosis/cirrhosis and HCC. (B)
Binding, uptake, internalization, and release of compounds targeted at extracellular receptors resulting in target cell-speciﬁc actions.
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Table 1. List of drugs targeted to HSC/myoﬁbroblasts and examined in vivo.
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 Galactose (lactose) targeted at the asialoglycoprotein receptor
(ASGP-R).
 Viruses: adeno and adeno-associated viruses binding to the
coxsackie and adenovirus cell adhesion receptor (CAR) or to
CD46.Activated cholangiocytes/hepatic progenitor cells
 RGD-analogs targeting the integrin avb6 (e.g., EMD524070).
 Secretin: targeting the secretin receptor.Hepatocellular carcinoma cells
 Monoclonal antibodies against:
EpCAM,
AF-20,
EGF-R.
 EGF – receptor binding oligopeptide.728 Journal of Hepatology 201Factors that dermine the success of a targeted drug
 Speciﬁc target receptor expression: expression on the target
cell relative to other key tissues and cells.
 High receptor afﬁnity of the drug carrier.
 High receptor density on target cells.
 Sufﬁcient stability of the construct in serum.
 Intracellular release of active compounds: endocytosis and
subsequent intracellular cleavage is required to ensure
release of the active compound from the drug carrier, which
is facilitated by an appropriate linker between drug and
carrier. The drug itself should either be resistant to the
endocytotic process or released extracellularly after binding
to its target receptor.
 Sufﬁcient amount of drug loaded on the carrier.
 Low immunogenicity of the construct.
 Size big enough to prevent immediate renal clearance, small
enough to ensure tissue penetration in the diseased area.
 Possibility of long-term treatment: low toxicity, appropriate
administration routes and intermediate-long biological half
life.
 Simpliﬁed synthesis according to GMP criteria.Conclusions
Cell-speciﬁcity is essential for most antiﬁbrogenic as well as
anticancer drugs. All key cells in the ﬁbrogenic process can be
reached by cell-speciﬁc drug carriers, and future research
should address the key factors that determine success. Coupling
of a tracer to a drug carrier also opens opportunities for diagno-
sis, early detection and individualized therapy monitoring, e.g.,
via quantitative imaging of liver ﬁbrosis, ﬁbrogenesis and can-
cer. This promises to facilitate a personalized medicine (sending
a drug and a tracer to the same cells) which is particular rele-
vant for chronic liver diseases, which subclinically progresses
to end-stage liver failure and which may need long-term
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